Loading...

PE/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_PECy7_030206
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
  • GK1dot5_PECy7_030206
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Save
100421 25 µg ¥15,670
100422 100 µg ¥38,270
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  2. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  3. Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
  4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  5. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  6. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  7. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  8. Xiong T, et al. 2022. Cancer Sci. 113:1955. PubMed
  9. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  10. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  11. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  12. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  13. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  14. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  15. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  16. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  17. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  18. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  19. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  20. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  21. Novaj A, et al. 2023. Int J Mol Sci. 24: . PubMed
  22. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  23. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  24. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  25. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
  26. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  27. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  28. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  29. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  30. Tang M, et al. 2023. Sci Adv. 9:eade6624. PubMed
  31. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  32. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
  33. Proietti M, et al. 2019. Nat Commun. 10:250. PubMed
  34. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  35. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  36. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  37. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  38. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  39. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  40. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  41. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  42. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  43. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  44. Crespo ÂC, et al. 2020. Cell. 182(5):1125-1139. PubMed
  45. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  46. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  47. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  48. Diao L, et al. 2022. iScience. 25:105511. PubMed
  49. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  50. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  51. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  52. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  53. Kaufmann U et al. 2019. Cell metabolism. 29(5):1104-1118 . PubMed
  54. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  55. Rolla S, et al. 2010. J Immunol. 184:6124. PubMed
  56. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  57. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  58. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  59. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  60. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  61. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  62. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  63. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
  64. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  65. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  66. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  67. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
  68. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  69. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  70. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  71. An J, et al. 2022. iScience. 25:103570. PubMed
  72. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  73. Ohmichi Y, et al. 2011. J Exp Med . 208:1015. PubMed
  74. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  75. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  76. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  77. Wang W, et al. 2020. Immunity. 51(6):1102-1118.e7.. PubMed
  78. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  79. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  80. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  81. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  82. Lee P, et al. 2014. J Immunol. 192:178. PubMed
  83. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  84. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  85. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  86. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  87. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  88. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  89. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  90. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  91. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  92. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  93. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  94. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  95. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
  96. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  97. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  98. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
  99. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
  100. XS R, et al. 2015. Diabetes. 64 90. PubMed
  101. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  102. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  103. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  104. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  105. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  106. Busse DC, et al. 2020. J Virol. 94:00:00. PubMed
  107. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  108. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  109. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  110. Kitajima Y, et al. 2022. Cells. 11:. PubMed
  111. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  112. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
  113. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  114. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  115. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  116. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  117. Wang W, et al. 2021. STAR Protocols. 2(3):100756. PubMed
  118. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  119. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  120. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  121. Li C, et al. 2018. Cell. 174:285. PubMed
  122. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
  123. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  124. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  125. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  126. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  127. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  128. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  129. Godwin MS, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 320:L393. PubMed
  130. Prüss H, et al. 2017. Nat Neurosci. 10.1038/nn.4643. PubMed
  131. Kimura S, et al. 2020. Am J Transplant. 20:977. PubMed
  132. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  133. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  134. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  135. Ambrosino E, et al. 2006. Cancer Res . 66:7734. PubMed
  136. Nagamata S, et al. 2019. Sci Rep. 9:3911. PubMed
  137. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  138. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  139. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  140. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  141. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
  142. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  143. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  144. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  145. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  146. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  147. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  148. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  149. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  150. Groves HT, et al. 2020. MBio. 11:e03236-19. PubMed
  151. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  152. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
  153. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_312706 (BioLegend Cat. No. 100421)
AB_312706 (BioLegend Cat. No. 100422)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account